Inclusion Criteria:

• Visually significant cataract planned for surgery

• Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma

• Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees <15 dB

• Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points <15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point <15 dB

• Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery

• Willing and able to understand and provide informed consent

• Willing and able to attend postoperative examinations per protocol schedule

Exclusion Criteria:

• Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation

• Selective laser trabeculoplasty within 90 days of study enrollment

• Iridotrabecular contact for 180 degrees or greater

• Peripheral anterior synechiae in nasal or inferior angle

• Best corrected visual acuity worse than 20/200

• Phacodonesis on pre-operative examination

• Vitreous in anterior chamber on pre-operative examination

• Nanophthalmos

• Anti-platelet and anticoagulant medications other than aspirin 81mg daily

• Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, steroids for corneal transplant)

• Abnormality in study eye that could affect tonometry

• Glaucoma diagnosis other than the above

• Normal tension glaucoma

• Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor)

• History of uveitis in either eye

• Inability to complete gonioscopy examination

• Use of oral steroids within 90 days or anticipated use of oral steroids

• Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide

• History of steroid-associated IOP elevation

• Medically unfit for attending planned study visits

• Involvement in another interventional research study

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 03/23/2026. Questions regarding updates should be directed to the study team contact.